MESO Mesoblast limited.

$MESO (L) Posted my Q2 call notes in Chat- another setup I see relatively little on elsewhere 1,100 patents/pending, IP to 2044 (long runway= high strategic value to acquirer) First-mover advantage (first and only mesenchymal stromal cell product approved by the FDA), complex manufacturing + unique know-how for scaling up $10B TAM in CLBP alone, then layer in SR-aGvHD, heart failure & DMD among others Also, burn rate of just $17.3M for back half of fiscal year (like how lean the operation is)

$MESO ridiculous that we still trade below 52 week high. This should and will soon climb higher

$MESO Q2 '26 Earnings Results & Recap For FY26, Mesoblast reported total revenues of $120.3M, driven by net product sales of $115.2M, and reduced its net loss by 44% to $57.5M, or 4.44 cents per share.

$MESO it’s been one year of b.s. sideways trading despite excellent execution imho we are WAY overdue for a run !!! Let’s go!!!

$MESO sideways drift until we get the next 4C and Ryoncil sales update in October. Barring any unexpectded news of course. The big catalysts are getting closer by the day! 12 months will see this being an entirely different company $$$

$MESO Mesoblast Reports Substantial Revenue Growth to US$120M Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: "We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. The financial result is a product of continued growth in RYONCIL market adoption and focus on disciplined capital allocation while investing in our high-value opportunities."

$MESO Keep an eye on MESO as each day is closer to the Ryoncil quarterly sales update, which the company has been releasing about the 10th of the month after quarter end. If sales have kept on their trend of increasing quarter over quarter, they are going to be very close to putting up a cash flow positive quarter!